Nuh (PTI): An oil tanker driver and his helper were killed while three occupants of a Rolls-Royce were injured when the heavy vehicle crashed into the luxury car on the Delhi-Mumbai-Baroda Expressway in this district, police said Wednesday.
The accident took place on Tuesday afternoon when the tanker, which was being driven on the wrong side, collided with the car near Umri village under Nagina police station limits, they said.
Police said the limousine immediately caught fire after colliding with the tanker, but all its five occupants were rescued in the nick of time by their relatives who were closely behind in another car.
Those killed in the crash were identified as tanker driver Rampreet and his helper Kuldeep, both residents of Uttar Pradesh, they said.
The three injured, occupants of the luxury car, were identified as Divya and Tasbir, residents of Chandigarh, and Vikas, a resident of Delhi, police said, adding they are being treated at Gurugram's Medanta Hospital.
Police reached the spot after getting information about the accident.
Assistant Sub-Inspector Ashok Kumar, the investigating officer, said an FIR will be registered after recording the statements of the injured.
The ASI said the family members of the accident victims have been informed about the accident.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Beijing, Sep 10: China’s top drug regulator has cleared a mpox vaccine developed by local drug firm Sinopharm for clinical trials which could be the country’s first experimental dose to battle the deadly disease.
The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon.
There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia.
In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval.
The process can take years, even decades. However, the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need, state-run China Daily reported on Tuesday.
According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA.
The description is the same as Jynneos, the world's first mpox vaccine approved by the Food and Drug Administration in the United States in 2019.
The World Health Organisation said on August 14 that the mpox outbreak in Africa constitutes a public health emergency of international concern — its highest form of alert.
Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases.
So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths.
China reported its first imported case in September 2022 and the first domestic case in June last year.
By the end of July, the nation had reported 2,567 confirmed cases, according to the China Daily report.